Beijing Airdoc Technology Co. Ltd. Class H
HHKEX:22518.60
HKD
-0.70
(-7.53%)
ISIN
CNE100004QQ9
Return %
Stock
S&P 500
1Y
-32.39
13.14
3Y
-23.89
80.78
5Y
- -
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Da Lei Zhang
- Full Time Employees
- 181
- Sector
- Technology services
- Industry
- Information technology services
- Address
- Building 2, A2 Yard Beijing BE China 100089
- IPO Date
- Nov 5, 2021
- Website
- airdoc.com
- Similar Companies
- Business
- Beijing Airdoc Technology Co., Ltd. (2251.HK) develops and provides AI-empowered retina-based early detection, diagnosis, health risk assessment, and treatment solutions for chronic and ophthalmic diseases; its core products include the Airdoc-AIFUNDUS SaMD series (Versions 1.0, 2.0, and 3.0) for diabetic retinopathy, hypertensive retinopathy, glaucoma, cataracts, pathological myopia, retinal detachment, and other fundus diseases; health risk assessment solutions covering 55 types of lesions and risks such as cardiovascular disease, anemia, dementia, and atrial fibrillation; AI-powered hardware like the AI-FUNDUSCAMERA-P portable fundus cameras, AI-FUNDUSCAMERA-M multimodal scanner, and in-house fundus cameras; myopia prevention products featuring PBM-LED light therapy devices and AI-driven intervention solutions; and visual training AI products with eye-tracking and personalized modules for strabismus, amblyopia, and vision rehabilitation, including all-in-one digital training machines and Vision Box hardware. Founded in 2015 and headquartered in Beijing, China, the company operates primarily in mainland China through subsidiaries and R&D centers in Shanghai, Guangzhou, Shenzhen, Hong Kong, Nanjing, Xi'an, Chengdu, and Wuhan, with expanding international presence in the European Union, Singapore, Thailand, Indonesia, Vietnam, South Africa, Saudi Arabia, the United Arab Emirates, and Malaysia via regulatory approvals for key products. It serves hospitals, primary healthcare institutions, health checkup centers, consumer healthcare settings like insurance firms and pharmacies, optometry centers, and eye health management platforms, targeting clinical departments, chronic disease screening, and pediatric vision care. Recent developments include the 2024 launch and January 2025 NMPA Class II certification of a new portable AI-optimized fundus camera for home and small B-end markets; NMPA approval in December 2024 for the pioneering PBM-LED myopia light therapy device and fundus function updates for AI-FUNDUSCAMERA-M in August 2024; submission of Airdoc-AIFUNDUS 2.0 registration in Q4 2024; a April 2024 partnership enhancing health services; deployment of WanYu Large Language Model-powered AI digital human "ikkie" with iKang; 40 new patents granted in 2024, totaling 270; and growth to 7,883 active service sites with 7.10 million cases served.